carmustine

(redirected from Gliadel)
Also found in: Medical.

car·mus·tine

 (kär′mŭs-tēn′)
n.
An antineoplastic drug, C5H9Cl2N3O2, used to treat various malignancies, including Hodgkin and non-Hodgkin lymphomas, melanoma, multiple myeloma, and brain tumors.

[Probably car(bamoylation), transfer of a carbamoyl group to an amino acid (the drug's method of inhibiting certain enzymes) + mustine, an anticancer drug (must(ard) + -ine).]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.
References in periodicals archive ?
Eisai also gained rights to the Gliadel Wafer, a chemotherapy agent, and Dacogen for myelodysplastic syndromes.
For recurrent GBM also not suitable for resection, a retrospective study by Kim et al., showed correlation of MGMT promoter methylation status with better progression free survival (PFS), and OS in patients who underwent gamma knife radiosurgery.8 MGMT methylation, and low MGMT expression were also identified as favourable prognostic markers in patients with newly diagnosed GBM, who underwent implantation of carmustine releasing wafers (Gliadel) after surgery.9
1997: The FDA approved Gliadel wafers for the treatment of recurrent GBM.
Westphal et al., "Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma," Neuro-Oncology, vol.
Subsequently, the patient was transferred to an outlying institution for additional management where he underwent reopening craniotomy with microsurgical resection of the tumor with Gliadel wafer placement approximately 17 weeks from his initial resection.
Bortey et al., "A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma," Neuro-Oncology, vol.
This trial enrolled 296 patients; one arm received IL-13PE and another received carmustine-releasing gliadel wafers (GW) via catheters implanted in the walls of the resection cavity after craniotomy.
In addition to Halaven being launched, the company currently has submitted the anticancer agent Gliadel, the antiepileptic agents Fycompa and Inovelon as well as the antiobesity agent BELVIQ for review.
Over the years, the wafer-based drug delivery technology originally conceived for a general drug delivery tool was developed to become the Gliadel, a wafer licensed by Esai Inc.